Diffuse Cutaneous Systemic Sclerosis Clinical Trials

39 clinical trials for Diffuse Cutaneous Systemic Sclerosis across international registries, including 8 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease — RECRUITING · PHASE1
• EncompaSSc: Evaluation of MTX-474 in Participants With Diffuse Cutaneous Systemic Sclerosis (dcSSc) — RECRUITING · PHASE2
• A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis — RECRUITING · PHASE2
• Controlling Hyperactive Immunity With Long-lived Lymphocytes — RECRUITING · PHASE1
• US Zamto-cel Autoimmune Diseases — RECRUITING · PHASE1
• Safety and Efficacy of Baricitinib on Skin Tightening in Diffuse Cutaneous Systemic Sclerosis: A Comparative Study With Methotrexate — RECRUITING · PHASE3
• Efficacy and Safety of Telitacicept in the Treatment of Systemic Sclerosis — RECRUITING · PHASE2
• Open Label Extension Study of Brentuximab Vedotin in Early dcSSc — RECRUITING · PHASE2
• A Phase 2 Randomized, Double-blind, Placebo-Controlled Study to Assess the Safety and Efficacy of MTX-474 in the Treatment of Participants with Diffuse Cutaneous Systemic Sclerosis (dcSSc) — NOT_YET_RECRUITING · PHASE2
• A Phase II, multi-part, five-year, randomized, open-label, assessor-blinded, active-controlled, multicenter study to evaluate the efficacy and safety of rapcabtagene autoleucel versus rituximab treatment in participants with severe refractory diffuse cutaneous systemic sclerosis — TERMINATED · PHASE2
• TL1A Inhibition in Systemic Sclerosis-Related Skin Fibrosis and Immunological Alterations: A Proof-of-Concept In Vitro Study (FIBROSTOP) — NOT_YET_RECRUITING
• Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007) — ACTIVE_NOT_RECRUITING · PHASE2
• Brentuximab Vedotin for Systemic Sclerosis — COMPLETED · PHASE1
• A randomized, double-blind, parallel group, placebo-controlled multicenter study to evaluate efficacy, safety and tolerability of ianalumab in participants with diffuse cutaneous systemic sclerosis — TERMINATED · PHASE2
• T-Guard against Autoreactive T cells in Systemic sclerosis: Erasion and Resolution (TASER) — TERMINATED · PHASE2
• A Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients With Diffuse Cutaneous Systemic Sclerosis — TERMINATED · PHASE2
• CARTIMMUNE: Study of Patients With Autoimmune Diseases Receiving KYV-101 — ACTIVE_NOT_RECRUITING · PHASE1
• A Study of CNTY-101 in Participants With Refractory B Cell-mediated Autoimmune Diseases — ACTIVE_NOT_RECRUITING · PHASE1
• An Open-label Extension Trial of HZNP-HZN-825-301 in Adult Participants With Diffuse Cutaneous Systemic Sclerosis (Diffuse Cutaneous SSc) — TERMINATED · PHASE2
• Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Diffuse Cutaneous Systemic Sclerosis — COMPLETED · PHASE2
• A Study to Evaluate the Safety and Tolerability of Oral Ixazomib in Scleroderma-related Lung Disease Patients — TERMINATED · PHASE2
• Extracorporeal Photopheresis in Early Diffuse Cutaneous Systemic Sclerosis — NOT_YET_RECRUITING · PHASE2
• A Randomized, Double-blind, Placebo-controlled, Repeat-dose, Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients with Diffuse Cutaneous Systemic Sclerosis [HZNP-HZN-825-301] — OTHER · PHASE2
• A Multicenter, Open-label Extension Trial to Evaluate the Efficacy, Safety and Tolerability of HZN-825 in Patients with Diffuse Cutaneous Systemic Sclerosis — OTHER · PHASE2
• A Study With TEPEZZA in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc) — TERMINATED · PHASE1
• Safety and Pharmacokinetics of IgPro20 and IgPro10 in Adults With Systemic Sclerosis (SSc) — COMPLETED · PHASE2
• Effectiveness of Bosentan Therapy in Patients With Systemic scleRosis and Progressive Digital ulcEr Disease. — OTHER
• A Safety and Efficacy Study of FCR001 in Adults With Rapidly Progressive Diffuse Cutaneous Systemic Sclerosis — WITHDRAWN · PHASE1
• Brentuximab Vedotin in Early Diffuse Cutaneous Systemic Sclerosis — COMPLETED · PHASE2
• Evaluation of Safety, Tolerability and Preliminary Efficacy of EHP-101 in Diffuse Cutaneous Systemic Sclerosis — SUSPENDED · PHASE2
• KD025 in Subjects With Diffuse Cutaneous Systemic Sclerosis — TERMINATED · PHASE2
• Efficacy and Safety of Belumosudil in Subjects With Diffuse Cutaneous Systemic Sclerosis — TERMINATED · PHASE2
• AN OPEN LABEL EXTENSION STUDY OF BRENTUXIMAB VEDOTIN TREATMENT IN ACTIVE DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS (DIFFUSE SCLERODERMA) — NOT_YET_RECRUITING
• Safety, Tolerability, Efficacy, and Pharmacokinetics of JBT-101 in Systemic Sclerosis — TERMINATED · PHASE2
• Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis — TERMINATED · PHASE3
• Efficacy and Safety of IgPro10 in Adults With Systemic Sclerosis (SSc) — WITHDRAWN · PHASE2
• A Study of Subcutaneous Abatacept to Treat Diffuse Cutaneous Systemic Sclerosis — COMPLETED · PHASE2
• Proof-of-concept Trial of IVA337 in Diffuse Cutaneous Systemic Sclerosis — COMPLETED · PHASE2
• Mycophenolate Mofetil in Systemic Sclerosis — COMPLETED · PHASE1

Refine this search